Complications of intravitreal injections in patients with diabetes (Q38261106)

1 September 2017

1 reference

title

Complications of intravitreal injections in patients with diabetes (English)

1 reference

1 September 2017

Hasanain Shikari

1

1 reference

1 September 2017

Paolo S Silva

series ordinal

2

1 reference

1 September 2017

Jennifer K Sun

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

Seminars in Ophthalmology

1 September 2017

1 reference

1 September 2017

29

1 reference

1 September 2017

5-6

1 reference

1 September 2017

276-289

1 reference

Intravitreal injection of therapeutic agents

1 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Etiology and treatment of macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Use of retinal procedures in medicare beneficiaries from 1997 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A review of clinical trials of anti-VEGF agents for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Diabetes mellitus and macrovascular disease: mechanisms and mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intricacies of bevacizumab-induced toxicities and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

VEGF inhibition, hypertension, and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A review on bevacizumab and surgical wound healing: an important warning to all surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Healing of partial thickness porcine skin wounds in a liquid environment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal ranibizumab and bevacizumab: a review of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Vascular endothelial growth factor biology: clinical implications for ocular treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Early breakdown of the blood-retinal barrier in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Evolving guidelines for intravitreous injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Prophylaxis of Endophthalmitis with Topical Povidone-iodine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Survey of intravitreal injection techniques among retinal specialists in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal triamcinolone for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Defining the normal bacterial flora of the oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Effect of lidocaine gel on povidone-iodine antisepsis and microbial survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Povidone-iodine before lidocaine gel anesthesia achieves surface antisepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Randomized trial of anesthetic methods for intravitreal injections.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Risks of intravitreous injection: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The etiology of steroid cataract

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Short-term results of intravitreal dexamethasone implant (OZURDEX(®)) in treatment of recalcitrant diabetic macular edema: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Clinical characteristics and surgical outcomes of pediatric rhegmatogenous retinal detachment in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intraocular pressure after intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Reducing the risk of endophthalmitis following intravitreal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A review of anti-VEGF agents for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820538.2014.962167

10.3109/08820538.2014.962167

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference